Alcohol Septal Ablation

Diagnosis and Management of Hypertrophic Cardiomyopathy

Volumn , Issue , 2007, Pages 259-278

  Seggewiss, Hubert ^a   Rigopoulos, Angelos ^b   Faber, Lothar ^c   Ziemssen, Peer ^a  

^a Leopoldina Krankenhaus   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Alcohol septal ablation; Hypertrophic obstructive cardiomyopathy; Myocardial infarction; Percutaneous transluminal septal myocardial ablation; Trifascicular block

Indexed keywords

EID: 84955632490     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987469.ch18     Document Type: Chapter

References (55)

1. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 1995; 92: 1680-92.
2. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardio-myopathy. N Engl J Med 1997; 336: 775-85.
3. Frank MJ, Abdulla AM, Canedo MI, Saylors RE. Long-term medical management of hy-pertrophic obstructive cardiomyopathy. Am J Cardiol 1978; 42: 993-1001.
4. Haberer T, Hess OM, Jenni R, Krayenbühl HP. Hypertrophic obstructive cardiomyopathy: Spontaneous course in comparison to long-term therapy with propanolol and verapamil. Z Kardiol 1983; 72: 487-93.
5. Harrison DC, Braunwald E, Glick G, Mason DT, Chidsey CA, Ross J Jr. Effects of beta ad-renergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 1964; 29: 84-98.
6. Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y. Treatment of hy-pertrophic obstructive cardiomyopathy with verapamil. Br Heart J 1979; 42: 35-42.
7. Pollick C. Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide: N Engl J Med 1982; 307: 997-9.
8. Kimball BP, Bui S, Wigle ED. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. Am Heart J 1993; 125: 1691-7.
9. Maron BJ. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: Too soon for a rush to judgment? J Am Coll Cardiol 1996; 27: 431-2.
10. Schulte HD, Gramsch-Zabel H, Schwartzkopff B. Hypertrophe obstruktive Kardiomyo-pathie: Chirurgische Behandlung. [In German.] Schweiz Med Wochenschr 1995; 125: 1940-9.
11. Robbins RC, Stinson EB, Daily PO. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996; 111:586-94.
12. Heric B, Lytle BW, Miller DP et al. Surgical management of hypertrophic obstructive car-diomyopathy: Early and late results. J Thorac Cardiovasc Surg 1995; 110: 195-208.
13. Schoendube FA, Klues HG, Reith S et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 1995; 92 (Suppl. II): 122-7
14. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: Evi-dence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994; 90: 2731-42.
15. Nishimura RA, Trusty JM, Hayes DL et al. Dual-chamber pacing for hypertrophic car-diomyopathy: A randomized, double-blind, crossover trial. J Am Coll Cardiol 1997; 29: 435-41.
16. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assess-ment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999; 99: 2927-33.
17. Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol 1999; 83: 903-7.
18. Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep 2001; 3: 160-6.
19. Brugada P, de Swart H, Smeets JL et al. Transcoronary chemical ablation of ventricular tachycardia. Circulation 1989; 79: 475-82.
20. Sigwart U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-14.
21. Kuhn H, Gietzen F, Leuner C et al. Induction of subaortic ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Eur Heart J 1997; 18: 846-51.
22. Seggewiss H, Gleichmann U, Faber L et al. Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy: Acute results and 3- month follow-up in 25 patients. J Am Coll Cardiol 1998; 31: 252-8.
23. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute and 3-months follow-up results with respect to myocardial contrast echocardiography. Circulation 1998; 98: 2415-21.
24. Faber L, Seggewiss H, Fassbender D et al. Guiding of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy by myocardial contrast echocardiography. J Intervent Cardiol 1998; 11: 443-8.
25. Ruzyllo W, Chojnowska L, Demkow M et al. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2000; 21: 770-7.
26. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-5.
27. Maron MS, Olivotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
28. Seggewiss H, Faber L, Meyners W et al. Simultaneous percutaneous treatment in hyper-trophic obstructive cardiomyopathy and coronary artery disease: A case report. Cathet Cardiovac Diagn 1998; 44: 65-9.
29. Knight C, Kurbaan AS, Seggewiss H et al. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 1997; 95: 2075-81.
30. Lakkis N, Kleiman N, Killip D et al. Hypertrophic obstructive cardiomyopathy: Alternative therapeutic options. Clin Cardiol 1997; 20: 417-18.
31. Bhargava B, Agarval R, Kaul U et al. Transcatheter alcohol ablation of the septum in a pa-tient of hypertrophic obstructive cardiomyopathy. Cathet Cardiovasc Diag 1997; 41: 56-8.
32. Kornacewicz-Jach Z, Gil R, Wojtarowicz A et al. Early results of alcohol ablation of the septal branch of coronary artery in patients with hypertrophic obstructive cardiomyopathy. [In Polish.] Kardiol Pol 1998; 48: 105-12.
33. Nagueh SF, Lakkis NM, He Z-X et al. Role of myocardial contrast echocardiography during nonsurgical reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1998; 32: 225-9.
34. Gietzen FH, Leuner CJ, Raute-Kreinsen U et al. Acute and long-term results after trans-coronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999; 20: 1342-54.
35. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hy-pertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999; 47: 94-100.
36. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myo-cardial ablation for hypertrophic obstructive cardiomyopathy: Long term follow up of the first series of 25 patients. Heart 2000; 83: 326-31.
37. Seggewiss H, Faber L, Ziemssen P et al. Age related acute results in percutaneous septal ablation in hypertrophic obstructive cardiomyopathy [abstract]. J Am Coll Cardiol 2000; 35 (Suppl. A): 188A.
38. Seggewiss H, Faber L, Ziemssen P, Meyners W. Non-surgical septal ablation (PTSMA) in patients with NYHA class IV and hypertrophic obstructive cardiomyopathy (HOCM) [abstract]. Circulation 1999; 100 (Suppl. I): 515.
39. Singh M, Edwards WD, Holmes DR Jr, Tajil AJ, Nishimura RA. Anatomy of the first septal perforating artery: A study with implications for ablation therapy for hypertrophic car-diomyopathy. Mayo Clin Proc 2001; 76: 799-802.
40. Seggewiss H, Faber L. Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction. Eur J Echocardiogr 2000; 1: 277-80.
41. Kern MJ, Holmes DG, Simpson C, Bitar SR, Rajjoub H. Delayed occurrence of complete heart block without warning after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Cathet Cardiovasc Intervent 2002; 56: 503-7.
42. Faber L, Seggewiss H, Werlemann BC, Fassbender D, Schmidt HK, Horstkotte D. Pre-diction of the risk of pacemaker dependency after percutaneous septal ablation for hy-pertrophic obstructive cardiomyopathy [abstract]. J Am Coll Cardiol 2002; 39 (Suppl. A): 845-3.
43. Kuhn H, Gietzen F, Leuner CH et al. Transcoronary ablation of septal hypertrophy: A new treatment for hypertrophic obstructive cardiomyopathy. Z Kardiol 2000; 89 (Suppl. 4): 41-54.
44. Welge D, Faber L, Werlemann BC et al. Long-term outcome after percutaneous septal ablation for hypertrophic obstructive cardiomyopathy [abstract]. J Am Coll Cardiol 2002; 39:845A.
45. Ziemssen P, Faber L, Schlichting J, Meyners W, Horstkotte D, Seggewiss H. Percutaneous septal ablation in patients with hypertrophic obstructive cardiomyopathy results in improvement of exercise capacity [abstract]. J Am Coll Cardiol 2000; 35: 182A.
46. Boekstegers P, Steinbigler P, Molnar A et al. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 846-53.
47. Mazur W, Lakkis NM, Nagueh SF et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 103: 1492-6.
48. Curtius JM, Stoecker J, Loesse B, Welslau R, Scholz D. Changes of the degree of hypertro-phy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment. Cardiology 1989; 76: 255-63.
49. Seggewiss H, Faber L, Ziemssen P, Gleichmann U. One year follow-up after echocardio- graphically-guided percutaneous septal ablation in hypertrophic obstructive cardiomy-opathy. [In German.] Dtsch Med Wochenschr 2001; 126: 424-30.
50. Seggewiss H, Faber L, Kleikamp G, Becker J, Gleichmann U. Hypertrophic obstructive cardiomyopathy and coronary artery disease: Surgical or interventional therapy [abstract]. Eur Heart J 1998; 19 (Suppl.): 624.
51. Qin JX, Shiota T, Lever HM et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001; 38: 1994-2000.
52. Nagueh SF, Ommen SR, Lakkis NM et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 1701-6.
53. Firoozi S, Elliott PM, Sharma S et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy: A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002; 23: 1617-24.
54. Wigle ED, Schwartz L, Woo A, Rakowski H. To ablate or operate? That is the question! J Am Coll Cardiol 2001; 38: 1707-10.
55. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: Clarification of patho-physiology and importance in intraoperative decision making. J Am Coll Cardiol 1992; 20: 53-4.